Trevena Inc.'s stock shot up this week on the news its post-operative pain drug met primary endpoints in a Phase IIb study – showing superiority over morphine.
Trevena Inc.'s stock shot up this week on the news its post-operative pain drug met primary endpoints in a Phase IIb study – showing superiority over morphine.
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Over the past few months, Chinese developers of CNS and cardiometabolic therapies have attracted the interest of domestic investors, amid generally modest funding activity.
Two Phase III trials testing tegoprazan read out positively, but the potassium-competitive acid blocker will compete with Phathom’s Voquezna (vonoprazan).
The biotech reported Phase I multiple-ascending dose data for its obesity drug for the second time in a week, but its safety and tolerability do not offset concerns about relatively unimpressive weight reduction.
The company announced positive topline results for the oral GLP-1 drug in type 2 diabetes that beat expectations.
JAK inhibitor gains ninth indication in US after a strong performance in the first quarter.
CSPC’s SYS6010, the first monospecific EGFR-targeting antibody-drug conjugate in the clinic for advanced NSCLC, has shown Phase I promise, but could face close competition with another China-originated bispecific.
Abeona plans to offer an outcomes-based payment model for Zevaskyn, which likely will see complementary use with Krystal’s Vyjuvek in recessive dystrophic epidermolysis bullosa patients.
